Invesco European Growth Fund Comments on MorphoSys

Author's Avatar
Sep 05, 2013
Article's Main Image
MorphoSys (MOR, Financial) is a German biotechnology company with proprietary technology to develop human antibodies for specific diseases. Over the quarter, the company signed two licensing deals (with GlaxoSmithKline PLC and Celgene Corp., not held by the fund) for its proprietary compounds, providing outside validation for its technology as well as upfront cash and future royalty payments.


From Invesco European Fund's second quarter commentary 2013.


Also check out:
Rating:
4 / 5 (3 votes)

Request A Demo

Learn more about GuruFocus' key features, including All-In-One Screener, backtesting, 30-year financial, stock summary page, guru trades, insider trades, excel Add-in, google sheets and much more.

GuruFocus Screeners

Related Articles